Firms

BioScience Managers

Melbourne, Victoria, Australia · London, United Kingdom · Türkiye

BioScience Managers is an international healthcare investment manager founded by Jeremy Curnock Cook in2003. Its Australian legal entity is BioScience Managers Pty Ltd (ACN124669192, ABN60124669192), a Corporate Authorised Representative of Phillip Asset Management Limited; its own history says it joined the PhillipCapital group inMay2004. The separate UK affiliate is BioScience Managers UK Ltd (company10921802, FRN823533), an appointed representative of Sturgeon Ventures LLP. These distinct contracting entities are not duplicate institutional buyers. The firm finances private and public healthcare companies with an emphasis on genomic medicine, paediatrics and digital technologies. Source-proven neuroscience/deeptech investments include Global Kinetics/PKG wearable Parkinson’s measurement, Saluda Medical closed-loop neuromodulation and Rex Bionics robotic rehabilitation. Its current directory identifies17 professionals across investment, operations, board and industry advisory work; advisor and board roles are kept distinct. David Atkins’ October2022 Managing Partner appointment is historical, since he is absent from the current directory. Four historical funds have actual raised amounts supported by the manager’s own history and fund page; VenturesII launched in2023 remains open with no verified closing amount/date. The Türkiye BioScience Managers fund is legally managed by Maxis, with BioScience Managers a collaborating healthcare investor; no separate duplicate subscriber check or unsupported USD100M close is assigned here. The government’s Global Kinetics cumulative AUD39.91M translation-fund investment figure is not a new financing round or individual2021 ticket. Exact LP closing days and legal vehicle mapping beyond published names remain unverified; corporate group AUM and commitments are excluded from closed fund cash. Public biographies sometimes retain old external-company roles, which are source-qualified as career history rather than current outside appointments.

Founded: 2003
Type: Venture capital

Funds5

Asia-Pacific Healthcare Fund II—A$56M
Own history identifies actual raised fund in2013; current fund page confirms published amount. Exact closing day and first/final lifecycle are not disclosed; no AUM or commitment substituted.
BioScience Managers Translation Fund I—A$101M
Own history identifies actual raised fund in2017; current fund page confirms published amount. Exact closing day and first/final lifecycle are not disclosed; no AUM or commitment substituted.
BioScience Managers Ventures Fund I—A$32M
Own history identifies actual raised fund in2017; current fund page confirms published amount. Exact closing day and first/final lifecycle are not disclosed; no AUM or commitment substituted.
BioScience Managers Ventures Fund II——
Launched2023 and currently open to investors; no verified actual closed corpus or closing day. Amount/date NULL, not treated as completed raise.
IB Australian Bioscience Fund I—A$42M
Own history identifies actual raised fund in2008; current fund page confirms published amount. Exact closing day and first/final lifecycle are not disclosed; no AUM or commitment substituted.